Background {#Sec1}
==========

Depression and anxiety are common mental disorders. The World Health Organization (WHO) has predicted that depression will become the second leading contributor to disease burden by the year 2020 \[[@CR1]\]. In different European studies, approximately 15 to 32 % of patients who visited primary health care centers showed symptoms of depression, anxiety, and stress-related disorders \[[@CR2]--[@CR5]\]. These in primary health care common psychiatric disorders are associated with poor quality of life and reduced life expectancy, placing a large economic burden on society. Several studies have explored the underlying pathophysiological and etiological mechanisms \[[@CR6]--[@CR8]\]. Current evidence suggests that the onset and progression of depression appear to be influenced by multiple factors, including neurotransmitter systems \[[@CR9], [@CR10]\], stress \[[@CR7], [@CR11]\], and genetic susceptibility \[[@CR7], [@CR12]\]. However, the molecular pathophysiology underlying depression and anxiety is still not fully understood. In recent years, the emergence of small noncoding RNAs as regulators of gene expression have gained much attention in various disease pathophysiologies. MicroRNAs are some of the most studied and well characterized among small noncoding RNAs. \[[@CR13]--[@CR17]\].

MicroRNAs (miRNAs) are a class of small (21-23-nucleotide), noncoding, single-stranded RNAs that inhibit gene expression by promoting messenger-RNA (mRNA) degradation or inhibiting translation \[[@CR18]\]. They influence a variety of physiological cell processes during development and tissue homeostasis by regulating the expression of around 90 % of all human genes \[[@CR19]\]. MicroRNAs are highly expressed in neurons, where they regulate processes of brain development, including neurogenesis, neuronal proliferation, metabolism, and apoptosis \[[@CR20]\]. Aberrant expression or dysregulation of miRNA processing has been linked to many neurological and psychiatric diseases. Studies in postmortem brains from patients with Alzheimer's disease, schizophrenia, bipolar disorder, and major depressive disorders showed alterations in several miRNAs \[[@CR21]--[@CR24]\]. Recently, numerous miRNAs have been detected in several body fluids, including serum, plasma, and cerebrospinal fluid (CSF) \[[@CR25]\]. The profile of circulating miRNAs changes significantly under pathological conditions compared to healthy conditions. Circulating miRNAs can be secreted from cells into the blood in different ways---enclosed in exosomes or associated with proteins \[[@CR26]--[@CR29]\]. They are resistant to nuclease digestion, and can be measured reproducibly, which makes them attractive as potential biomarkers.

Over the past several years, circulating miRNAs, as potential biomarkers, have been well documented in many diseases, including cancer, diabetes, and psychiatric diseases \[[@CR13]--[@CR15], [@CR30]--[@CR32]\]. Recently, two studies have examined circulating miRNA expression in the blood in patients with major depressive disorder \[[@CR31], [@CR33]\] and found some dysregulated miRNAs. However, these studies only had small numbers of patients with a focus on major depressive disorders. A systematic analysis of plasma miRNAs in depression and anxiety has so far not been performed.

The present study builds on a previously published randomized controlled trial by our group, where we included patients with depression/anxiety from 16 primary health care centers \[[@CR34]\] in Sweden in order to compare the effects of mindfulness treatment with treatment as usual on depressive/anxiety symptoms. In the present study, we hypothesized that patients with depression/anxiety would experience a significant change in plasma miRNAs after an 8-week treatment and that there would be an association between plasma miRNA levels and symptoms of depression/anxiety at baseline. Using a broad miRNA screening panel, we identified a group of miRNAs whose expression differed between baseline and follow-up using plasma samples from 11 patients who showed a decline in the Montgomery-Åsberg Depression Rating Scale (MADRS-S) total score of at least 50 % between baseline and follow-up. The first aim was to examine whether the miRNAs that were identified as differentially expressed after treatment were associated with a response to treatment. The second aim was to examine the association between these differentially expressed miRNAs and symptoms of depression/anxiety at baseline.

Results {#Sec2}
=======

Patients' characteristics {#Sec3}
-------------------------

The clinical characteristics of the patients are shown in Table [1](#Tab1){ref-type="table"}. The mean age in the whole group was 42 years and more of the participants were women. Most antidepressants prescribed at primary health care centers in Sweden are selective serotonin reuptake inhibitor (SSRIs) (e.g., citalopram, fluoxetine, and sertraline, data not shown). The median scores at baseline indicated mild to moderate symptoms of depression and/or anxiety. After treatment, the median scores decreased, indicating none to mild symptoms. A total of 39 % of the patients had a decrease in MADRS-S score of at least 50 % after the 8-week treatment compared to baseline (data not shown in tables).Table 1Characteristics of the patients in the whole cohortVariableThe whole cohort (*n* = 169)Baseline MADRS-S20 (11)Median score (IQR)Follow-up MADRS-S11 (10)Median score (IQR)Baseline HADS-D8 (5)Median score (IQR)Follow-up HADS-D4 (4)Median score (IQR)Baseline HADS-A12 (5.7)Median score (IQR)Follow-up HADS-A7 (4)Median score (IQR)Baseline PHQ-912 (9)Median score (IQR)Follow-up PHQ-96 (6)Median score (IQR)Age, years42 (11)Mean (SD)Sex13/86Male/female (%)Antidepressants^a^34/57Yes/no (%)Tranquilizers^a^14/72Yes/no (%)*IQR* interquartile range, *SD* standard deviation^a^16 patients had missing data for antidepressants, and 24 had missing data for tranquilizers

miRNAs screening data {#Sec4}
---------------------

To increase the chances of identifying miRNAs that are associated with treatment response, we performed initial screening of plasma from 11 patients with at least a 50 % decline in MADRS-S total score at follow-up. Six candidate miRNAs with a \>1.5 fold differential expressions between baseline and follow-up were selected (Additional file [1](#MOESM1){ref-type="media"}: Table S1): miR-144-5p, miR-92b-3p, miR-885-5p, miR-30a-5p, miR-29a-5p, and miR-29b-2-5p. These six miRNAs were then measured in the entire cohort. Five of them were detectable in all samples, but miR-885 was not suitable for further analysis as more than 20 % of patients had Ct values of \>35.

Response analysis {#Sec5}
-----------------

The selected five miRNAs were validated in all of the 169 patients at baseline and follow-up. Additional file [2](#MOESM2){ref-type="media"}: Figure S1 shows that after treatment, the mean plasma miR-144-5p level and miR-30a-5p in the depression/anxiety patients increased significantly compared to baseline, (*p* \< 0.0001 and *p* = 0.007, respectively). Moreover, to assess the potential association between candidates' miRNAs and treatment response, we performed linear regression analysis between miRNAs changes (∆∆Ct) and MADRS score change in the patients. However, no significant associations were found between the changes of those selected miRNAs and MADRS-S score change after treatment (Table [2](#Tab2){ref-type="table"}).Table 2Associations between selected miRNAs (∆∆Ct = ∆Ct~follow-up~-∆Ct~baseline~) and change in MADRS-S for all patients, adjusted for MADRS-S at baseline, as determined using linear regressionUnivariate analysis*βp* value95 % CImiR-144-5p (*n* = 160)MADRS-S−0.0040.68−0.02; 0.01miR-29a-5p (*n* = 153)^a^MADRS-S−0.0050.65−0.02; 0.02miR-*29b*-*2*-*5p* (*n* = 153)^a^MADRS-S−0.0020.82−0.02; 0.02miR-30a-5p (*n* = 153)^a^MADRS-S0.0030.72−0.01; 0.02miR-92b-3p (*n* = 160)^a^MADRS-S−0.0050.67−0.03; 0.02^a^Information (clinical or qRT-PCR) is missing for some patients (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"})

Associations of miRNAs with symptoms of depression/anxiety (cross-sectional study) {#Sec6}
----------------------------------------------------------------------------------

Unadjusted linear regression revealed that plasma miR-144-5p expression level at baseline was inversely related to MADRS-S score at baseline (*β* = −0.02, *p* \< 0.01) (Table [3](#Tab3){ref-type="table"}). Adjustment for sex and age did not affect these values. The lower the plasma miR-144-5p expression levels were the higher was the depression score. Like miR-144-5p, miR-29a-5p showed a significant positive association with MADRS-S score (*β* = 0.02, *p* = 0.04) in the unadjusted regression. After adjustment for age and sex, the *p* value (0.06) no longer remained significant (Table [3](#Tab3){ref-type="table"}). We also corrected for multiple testing according to Bonferroni. We adjusted the individual *p* value for each of these five miRNAs and found that the association between miR-144-5p and the MADRS-S at baseline was still significant. The relationships between miR-144-5p and the scores at baseline are also shown for the other two scales (Additional file [1](#MOESM1){ref-type="media"}: Table S2a, b). The overall pattern for the other two scales was similar to the results for MADRS-S.Table 3Associations between selected miRNAs (∆Ct at baseline) and MADRS-S for the whole cohort, as determined using linear regressionUnivariate analysisAdjusted analysis*βp* value95 % CI*βp* value95 % CImiR-144-5p (*n* = 166)MADRS-S at baseline−0.020.009−0.03; −0.005−0.020.008−0.03; −0.005Sex (female vs. male)−0.340.03−0.64; −0.04Age0.0050.28−0.004; 0.01miR-29a-5p (*n* = 159)^a^MADRS-S at baseline0.020.040.0004; 0.030.010.06−0.0005; 0.03Sex (female vs. male)−0.0070.97−0.35; 0.34Age−0.010.04−0.02; −0.0007miR-29b-2-5p (*n* = 159)^a^MADRS-S at baseline0.0040.62−0.01; 0.020.0040.61−0.01; 0.02Sex (female vs. male)−0.180.30−0.53; 0.16Age0.0050.39−0.006; 0.01miR-30a-5p (*n* = 159)^a^MADRS-S at baseline0.0020.73−0.01; 0.020.0030.68−0.01; 0.02Sex (female vs. male)0.240.14−0.07; 0.55Age0.00060.90−0.009; 0.01miR-92b-3p (*n* = 166)^a^MADRS-S at baseline0.010.11−0.002; 0.020.010.12−0.002; 0.02Sex (female vs. male)0.040.78−0.23; 0.30Age−0.0030.51−0.01; 0.005^a^Information (clinical or qRT-PCR) is missing for some patients (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"})

Comparison of miR-144-5p expression in depression/anxiety patients and healthy controls {#Sec7}
---------------------------------------------------------------------------------------

Figure [1](#Fig1){ref-type="fig"} shows the relative plasma miR-144-5p expression levels in the healthy controls and the depression/anxiety patients before and after the 8-week treatment. The relative miR-144-5p expression levels at both baseline and after treatment were significantly lower in the depression/anxiety patients than in the healthy controls (*p* \< 0.001). In the depression/anxiety patients, the mean plasma miR-144-5p level increased significantly after treatment compared to baseline (*p* \< 0.0001).Fig. 1Plasma miR-144-5p levels (determined by the 2ΔCt method): data are shown as the mean and 95 % CI. \**p*: paired *t* test), \#*p*: linear regression

Discussion {#Sec8}
==========

To our knowledge, this is the first study to investigate the expression of miRNAs in primary health care patients with depression/anxiety. Our major findings are that plasma expression levels of miR-144-5p were inversely associated with depression scores at baseline and that plasma miR-144-5p levels in depressive patients were significantly lower than in healthy controls. These findings suggest that miRNA-144-5p may reflect the pathologic processes of depression. Moreover, we found that plasma levels of miRNA-144-5p were significantly higher after treatment compared to baseline levels in depression/anxiety patients. No significant associations were found between the changes of those differentially expressed miRNAs and MADRS-S score change after treatment (response analysis).

The finding of an inverse correlation between plasma miR-144-5p levels and the MADRS-S at baseline was also present for the other two depression scores, i.e., Hospital Anxiety and Depression Scale (HADS)-D and PHQ-9; however, the results for HADS-D and PHQ-9 did not reach statistical significance. We applied correction for multiple testing according to Bonferroni, and the lack of significance for HADS-D and PHQ-9 may be due to the sample size in combination with the Bonferroni correction. An advantage with the MADRS-S is that it is a commonly used scale for depression \[[@CR35], [@CR36]\], which is sensitive to discriminate the severity of depression and it is therefore preferred in studies where the intention is to measure core depressive symptoms and states \[[@CR37]\].

The presentation of depressive syndromes is heterogeneous. Thus, identifying patients with depression using only depression scores or patient self-report may lead to a delayed or even wrong diagnosis \[[@CR38], [@CR39]\]. It is thus necessary to identify stable biomarkers to help with the clinical diagnosis of depression and elucidate potential biological mechanisms. A stable biomarker that is easily assessed in peripheral blood might be an ideal and objective measure to diagnose or evaluate the stage of depression \[[@CR40]\]. Such biomarkers are still lacking. Circulating miRNAs are stable and easily accessible, which may enable their application in daily clinical practice. Studies have reported that circulating miRNAs are released from specific cells and transferred to recipient cells to exert their function \[[@CR41]\]. Furthermore, aberrant expression of circulating miRNAs was demonstrated to be related to tissue injury \[[@CR42]\], which raises the possibility of blood-based miRNA profiles as fingerprints of diseases. Based on the evidence described above, the notion of circulating miRNAs as biomarkers for various diseases has been expressed.

Strengths of our study are that the present results were obtained from an randomized controlled trial (RCT) including a total of 169 patients, who are representative of patients in primary health care. Furthermore, this is the first study to provide evidence that a specific miRNA may serve as a potential biomarker for the diagnosis of depression. Presently, the role of circulating miR-144-5p in depressive disorders remains unclear. However, there are a few biological mechanisms that can explain our finding.

MiR-144 has broad expression and is enriched in brain, as well as in normal and malignant hematopoietic cells and tissues \[[@CR43]\]. It is highly conserved and has multiple predicted targets in both humans and rats \[[@CR44]\]. Many studies have demonstrated that miR-144 is involved in the response to mood stabilizer treatment \[[@CR45]\], stress responses \[[@CR46], [@CR47]\], and aging diseases \[[@CR48]\]. Long-term treatment with the mood stabilizers lithium and valproate significantly up-regulates miR-144 expression in the rat hippocampus, which is one of the brain regions involved in mood regulation. Signaling pathways targeted by miR-144 include the protein kinase C (PKC), Wnt/β-catenin, and PTEN pathways \[[@CR45]\]. Some of them have been shown to be involved in the development of depression \[[@CR49], [@CR50]\]. In addition, miR-144 was reported to be selectively up-regulated in the aging brain of humans and was suggested to have neuroprotective functions. miR-144 can inhibit the expression of ataxin 1 (ATXN1) in human cells, and a search of the Genetic Association Database shows that ATXN1 is associated with mental disorders, such as bipolar disorder, schizophrenia, and major depressive disorder \[[@CR48]\]. It is known that stress is an important risk factor for depression. In one study, circulating miR-144\* level changed with stress associated with the nationally administered examination for academic promotion in healthy young adults: miR-144\* level was significantly increased after the examination compared to before the examination \[[@CR46]\]. However, there was no correlation between miR-144\* level and anxiety scores \[[@CR46]\], which is consistent with our findings (Additional file [1](#MOESM1){ref-type="media"}: Table S2b). We assume that the increased circulating miR-144 level may reflect changes in miR-144 expression in the brain, which may in turn be associated with the progression of depression. The psychopathological mechanisms of the effect of miR-144 on depression remain to be elucidated. Our results, however, is a complement to the recent findings that decreased levels of miR-144\* are associated with several diseases \[[@CR51], [@CR52]\].

Our study is the first RCT to explore the association of circulating miRNA expression in depression. Despite our promising results, there are several general limitations to our experimental design that should be considered when interpreting our results. First, we included patients with depression as well as anxiety. Overlapping symptoms could affect our findings. However, overlapping symptoms are relatively common among these conditions and our approach is in line with previous studies. Second, in the initial screening analysis, we ran one well instead of duplicates/triplicates for each sample. However, when we setup technical replicates (duplicates or triplicates) in our laboratory, the technical variation was very small. Another limitation is that only six miRNAs were selected from the initial miRNA screen and validated in the whole cohort, suggesting that other miRNAs that are potentially associated with depression scores could have been missed in the current study. However, these selected miRNAs were the only miRNAs that were differentially expressed. In addition, this is the first study to examine miRNAs' potential association with depression/anxiety, and there is so far no available standard for selection of candidate miRNAs for screening. In addition, the correlation between plasma miR-144-5p expression level and miR-144-5p in the brain is unknown, as is the source of plasma miR-144-5p.

Conclusions {#Sec9}
===========

In summary, our findings show that plasma miR-144-5p levels are associated with depressive symptoms in a primary health care setting. In further studies, plasma miR-144-5p levels need to be measured in patients in other clinical settings, including major depressive disorders, to examine the validity of our findings. It will also be of interest to examine whether the expression of exosomal miR-144-5p is related to depression scores. In addition, it would be informative to test the predictive value of miR-144-5p in a larger cohort of patients with depression.

Methods {#Sec10}
=======

Study subjects and sample collection {#Sec11}
------------------------------------

The study subjects were recruited from 16 primary health care centers in a RCT of mindfulness group therapy compared to treatment as usual. The RCT included a group of patients with depression, anxiety or stress, and adjustment disorder. A detailed description of the study design is provided in our previous article \[[@CR34]\]. The overall aim of the RCT was to compare the effect of a structured mindfulness-based group therapy program with treatment as usual (mostly individual cognitive behavioral therapy (CBT)) \[[@CR53]\]. Briefly, patients were recruited between 4 Jan 2012 and 22 March 2012 at the 16 primary health centers in urban and rural settings in Skåne, in the southernmost part of Sweden. The inclusion criteria were as follows: age 20--64 years and a score of ≥10 on the Patient Health Questionnaire (PHQ)-9 or ≥7 on the HADS or a total score on the MADRS-S of between 13 and 34 (mild to moderate depression). A total of 135 patients met the inclusion criteria for MADRS-S, 118 for HADS-A, 159 for HADS-D, and 111 for PHQ-9. The rationale for using multiple scales to assess symptoms of depression and anxiety was that different scales are used in clinical practices worldwide \[[@CR34]\]. Eligible patients had a clinical diagnosis of depression, anxiety or stress, and adjustment disorder, according to the International Classification of Diseases (ICD)-10 criteria. All clinical diagnoses were made by doctors at the 16 primary health care centers. The exclusion criteria were as follows: severe personality disorder, risk of suicide, pregnancy, thyroid disease, current psychotherapy of any kind, and participation in any other psychiatric intervention study. The clinical characteristics and miRNA distributions of the total study population are presented in Table [1](#Tab1){ref-type="table"}. In total, 169 patients (86 % females, 13 % males, 1 % gender not specified) aged 42 ± 11 years (mean ± standard deviation) were enrolled in the present study. All the patients were fluent in Swedish, and 90 % were born in Sweden and/or had at least a high school degree (not shown in table). Each patient filled in three self-rated questionnaires (above mentioned PHQ-9, HADS-A/HADS-D, and MADRS-S) at baseline and after 8 weeks of follow-up. The patients received antidepressants and tranquilizers if deemed necessary. Blood samples were collected at the same time as the assessment of self-rated symptoms before and after treatment. The control group was consisted of 52 healthy individuals (74 % females, 26 % males) aged 47 ± 12 years. They were recruited from all types of personnel groups among the hospital staff.

Plasma collection {#Sec12}
-----------------

For patients, whole blood (6 mL) was collected from each participant in EDTA tubes. Blood samples were centrifuged at 2000 g for 10 min at 4 °C, and the plasma was then aliquoted and stored at −80 °C before further processing. For healthy controls, whole blood was collected in buffered citrate tubes and centrifuged at 2000 g for 20 min at room temperature. Blood samples were processed and plasma frozen within 8 h of collection.

Sampling strategy and miRNA analysis {#Sec13}
------------------------------------

For the miRNA screening, 11 individuals (8 females and 3 males, age 41 ± 9. 2 years) with a minimum reduction in MADRS-S score of 50 % from the initial evaluation were selected. We selected those individuals who showed the largest change in the magnitude of the depressive symptoms. We assumed that a linear change in the magnitude of the depressive symptoms would also be associated with the magnitude of the depressive/anxiety symptoms at baseline.

We used MADRS-S score as our selection criteria because it is a commonly used scale for depression \[[@CR31], [@CR35], [@CR36], [@CR54]\]. The individuals in this initial screening analysis were chosen to resemble the whole group as much as possible, based on sex and age. Fifty microliter of total RNA was isolated from 200 μl of plasma using the Qiagen miRNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's protocol, with minor modifications. miRNAs were reverse transcribed using a Universal cDNA Synthesis kit (Exiqon, Vedbæk, Denmark). The resulting reverse transcription reaction product was stored at −20 °C before analysis. A detailed description of the methodology is provided in a previous article \[[@CR30]\]. miRNA expression was screened using a Serum/Plasma Focus microRNA PCR Panel (Exiqon) comprising 179 LNA™ microRNA primer sets focusing on serum/plasma-relevant human miRNAs. Quantitative real-time PCR (qPCR) was conducted using a CFX384 Real-Time PCR Detection System (Bio-Rad). Undetectable data were assigned a default threshold cycle (Ct) value of 36. A mean of 172 miRNAs were detected in the 11 samples. As there is no current consensus as to an appropriate reference miRNA for the normalization of plasma miRNAs in qPCR analysis, all qPCR data were normalized to the Ct average of all miRNA measurements for each sample \[[@CR55]\]. Comparison of the 172 miRNAs in the 11 samples revealed six miRNAs with \>1.5 fold differential expression between baseline and follow-up (Additional file [1](#MOESM1){ref-type="media"}: Table S1). We used a \>1.5 fold change between baseline and follow-up as the cutoff, which is based on several previous profiling studies confirming that a \>1.5 fold change in miRNA expression can have a significant impact on the biology of the cell \[[@CR55]--[@CR57]\]. These six miRNAs were then measured in duplicate by qPCR in the whole cohort (*n* = 169). miR-451a and miR-23a-3p were used to test hemolysis in plasma samples \[[@CR58]\]. The Ct values were normalized according to the ∆Ct method with the internal controls miR-425-5p and miR-186-5p. The normalization stability of those two miRNAs was confirmed with geNorm software \[[@CR59]\]. Ct values were normalized to miR-425-5p and miR-186-5p using the following equation: ∆Ct = Ct~miR-425-5p~&~miR-186-5p~ (geometric mean of two miRNAs) − Ct~miR\ of\ interest~. Relative expression was calculated as 2^∆Ct^.

Ethical considerations {#Sec14}
----------------------

The study was performed according to the principles of the Declaration of Helsinki. It was reviewed and approved by the Ethics Committee of Lund University, prior to its commencement, on 5 October 2011 (application no. 2011/491). Written informed consent was obtained from all participants.

Statistical analysis {#Sec15}
--------------------

For the miRNA screening analysis, we tested the difference between baseline and follow-up using the Wilcoxon signed-rank test due to the nature of data, repeated measurements and nonnormality (Additional file [1](#MOESM1){ref-type="media"}: Table S1). MADRS-S, HADS-D (depression), HADS-A (anxiety), and PHQ-9 scores are presented as the median and interquartile range (IQR); age is presented as the mean and standard deviation (SD); and sex and antidepressant and tranquilizer use are presented as numbers and percentages (Table [1](#Tab1){ref-type="table"}). The mean and 95 % confidence interval (CI) at baseline and follow-up are shown for plasma miR-144-5p levels. A paired *t* test was used to test the difference between baseline and follow-up (Additional file [2](#MOESM2){ref-type="media"}: Figure S1). The association between change in miRNA levels and treatment response was tested using linear regression, adjusted for MADRS-S at baseline (Table [2](#Tab2){ref-type="table"}). Linear regression was also used to examine the associations between miRNA levels at baseline and MADRS-S, HADS-D, HADS-A, and PHQ-9 scores (Table [3](#Tab3){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S2a-S2c). We considered important potential confounders to be sex, age, drug treatment (antidepressant and/or tranquilizer), body mass index (BMI), and smoking. When adjusting the models for these variables, the beta-coefficients did not change much (at the most 5 %) and no *p* values were significant for drug treatment, BMI, or smoking. Hence, we kept in the final models only sex and age as adjusting variables.

Linear regression analyses (adjusted for age and sex) were used to test the difference of miR-144-5p levels between healthy controls and patients at baseline and after treatment (Figure [1](#Fig1){ref-type="fig"}). STATA version 12 (StataCorp LP) was used for all statistical analyses.

Additional files {#Sec16}
================

Additional file 1:**Supplementary Tables. Table S1.** six candidate miRNAs with \>1.5 fold differential expression between baseline and follow-up and changes in more than half of the samples (n≥6) were selected for further validation. **Table S2a and Table S2b.** The relationships between miR-144-5p and two depression scores at baseline, HADS-D (β=-0.02, p=0.02) and PHQ-9 (β=-0.02, p=0.06) were also significant or borderline significant, whereas the association with HADS-A score (β=-0.01, p=0.37) was non-significant **(Table S2c)**.Additional file 2: Figure S1.Supplementary Figure. Plasma 5 miRNAs levels (determined by the 2ΔCt method)changed after treatment. Data are shown as the mean and 95 % CI. P calculated with paired t-test
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